HLA-E, which binds to the inhibitory CD94/NKG2A receptor expressed by activated NK cells and CD8 T cells, can directly suppress innate and adaptive immunity when expressed by cancer cells [24, 25]. This evidence concerns the gene HLA-E and cancer.